Pieter E. Postmus, MD, PhD

home / authors / pieter-e-postmus-md-phd

Articles

Cisplatin and Paclitaxel for Non–Small-Cell Lung Cancer: The European Experience

September 1st 1999

Many physicians have questioned whether the additional survival benefit gained from the use of combination chemotherapy in non–small-cell lung cancer has been offset by chemotherapy-induced toxicity, particularly with

Small-Cell Lung Cancer: Is There a Standard Therapy?

Pieter E. Postmus, MD, PhD;Egbert F. Smit, MD

January 2nd 1998

For more than 25 years, chemotherapy has been the cornerstone of treatment for small-cell lung cancer. Many studies have tested a wide variety of drugs in different combinations, resulting in a number of standard

Cisplatin/Paclitaxel vs Cisplatin/Teniposide for Advanced Non-Small-Cell Lung Cancer

Giuseppe Giaccone, MD, PhD;Pieter E. Postmus, MD, PhD;Ted A. W. Splinter, MD;Maria Diaz-puente, MD;Nico Van Zandwijk, MD, PhD;Giorgio V. Scagliotti, MD, PhD;Andrea Ardizzoni, MD;Jan Van Meerbeeck, MD;Channa Debruyne, MD;Tarek Sahmoud, MD

April 1st 1997

A total of 332 patients with advanced non-small-cell lung cancer were randomized by the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative